Related Experiment Video
Updated: Oct 6, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance - a review
Lingyun Zhou1,2, Jintao He1,2, Wenbing Huang1,2
1Department of Biochemistry and Molecular Biology, Health Science Center, College of Basic Medical Sciences, Dali University, Dali, China.
Abstract:
Malignant tumors remain a leading cause of global mortality, and the development of chemoresistance represents a major obstacle to effective cancer treatment. Long non-coding RNAs (lncRNAs) are important regulators of tumor progression and therapeutic response. Cancer susceptibility candidate 2 (CASC2) is an lncRNA that is generally downregulated in malignant tumors and has been implicated in the regulation of chemoresistance. CASC2 influences therapeutic responsiveness through multiple mechanisms, including modulation of apoptosis and oncogenic signaling pathways, competitive binding to specific miRNAs, regulation of protein stability and RNA-protein interactions, and epigenetic gene regulation. Notably, its effects may vary according to tumor type and treatment context. This review systematically summarizes the regulatory roles and molecular mechanisms of CASC2 in tumor chemoresistance and discusses its potential clinical and therapeutic implications.
Related Concept Videos
Treatment Resistant Cancers
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...